Please ensure Javascript is enabled for purposes of website accessibility

Why NuVasive, Inc. Stock Jumped Today

By Keith Speights - Updated Aug 1, 2018 at 4:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered, as short-term pain in the first half of 2018 for NuVasive could lead to a stronger performance in the future.

What happened

Shares of NuVasive, Inc. (NUVA 0.76%) jumped 11.6% higher on Wednesday. The medical-device maker, which focuses on spine-surgery technology, announced its second-quarter earnings results after the market closed on Tuesday.

After posting a GAAP (generally accepted accounting principles) net loss in the first quarter due to a one-time item, NuVasive roared back in Q2. The company's revenue rose 8.5% year over year to $281.6 million. NuVasive reported non-GAAP diluted earnings per share (EPS) of $0.58, a 29% increase from the prior-year period. NuVasive lowered its full-year earnings guidance, however: The company now expects 2018 non-GAAP EPS of between $2.37 and $2.40, compared to its previous guidance of $2.44 to $2.47.

So why did NuVasive's share price move higher instead of falling? Probably because the company has addressed production bottlenecks at its West Carrollton, Ohio, manufacturing facility, and anticipates improved throughput and profitability in 2019 as a result.

Pointing to image of spine on monitor

Image source: Getty Images.

So what

The market's reaction to NuVasive's Q2 earnings update underscores why the future is more important than the past when it comes to investing. NuVasive certainly had a pretty good quarter, with growing revenue and earnings. However, the company met the consensus Wall Street earnings estimate rather than beating it.

Although NuVasive lowered its full-year guidance a little, it appears that investors took the negative revision in stride. That's likely because the company said that it has resolved the issues at its West Carrollton facility that led to the weaker full-year outlook.

While didn't provide any guidance for 2019, the company should be in good position for higher growth then. CFO Rajesh Asarpota stated in the Q2 earnings call that remains on track to achieve an operating margin of 25% -- much higher than the 16.7% margin projected for this year.

Now what

Investors should now be able to look forward to better news from in the months to come. In addition to benefiting from the resolution of its manufacturing facility problems, the company also should begin to see the fruits of the new products it launched from late 2017 onward.

The stock is still a bit pricey, though, with a forward earnings multiple of 23. It's still possible that any hiccups could result in more volatility like this year's. Still, appears to be on the right track now.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends NuVasive. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NuVasive, Inc. Stock Quote
NuVasive, Inc.
NUVA
$51.86 (0.76%) $0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.